Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Douillard, K. Oliner, S. Siena, J. Tabernero, R. Burkes, M. Barugel, Y. Humblet, G. Bodoky, D. Cunningham, J. Jassem, F. Rivera, I. Kocáková, P. Ruff, M. Błasińska-Morawiec, M. Šmakal, J. Canon, M. Rother, R. Williams, A. Rong, J. Wiezorek, R. Sidhu, S. Patterson (2013)Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
The New England journal of medicine, 369 11
W John, J Picus, CD Blanke, JW Clark, LN Schulman, EK Rowinsky (2000)Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study
NS Goldstein, M Armin (2001)Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system
C. Cripps, M. Burnell, J. Jolivet, G. Batist, W. Lofters, J. Dancey, J. Iglesias, B. Fisher, E. Eisenhauer (1999)Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study.
Annals of oncology : official journal of the European Society for Medical Oncology, 10 10
R. Siegel, K. Miller, A. Jemal (2019)Cancer statistics, 2019
CA: A Cancer Journal for Clinicians, 69
D. Salomon, R. Brandt, F. Ciardiello, N. Normanno (1995)Epidermal growth factor-related peptides and their receptors in human malignancies.
Critical reviews in oncology/hematology, 19 3
F. Bibeau, F. Boissière-Michot, J. Sabourin, S. Gourgou-Bourgade, M. Radal, F. Penault-Llorca, P. Rochaix, L. Arnould, M. Bralet, D. Azria, M. Ychou (2006)Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray
Virchows Archiv, 449
M. Resnick, J. Routhier, T. Konkin, E. Sabo, V. Pricolo (2004)Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study.
Clinical cancer research : an official journal of the American Association for Cancer Research, 10 9
C. Shih, V. Chen, L. Gossett, S. Gates, C. MackellarWarren, L. Habeck, Katherine Shackelford, L. Mendelsohn, D. Soose, V. Patel, S. Andis, J. Bewley, E. Rayl, B. Moroson, G. Beardsley, W. Kohler, M. Ratnam, R. Schultz (1997)LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
Cancer research, 57 6
J. McKay, Lesley Murray, S. Curran, V. Ross, C. Clark, G. Murray, J. Cassidy, H. McLeod (2002)Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases.
European journal of cancer, 38 17
Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on
A. Grothey, E. Cutsem, A. Sobrero, S. Siena, A. Falcone, M. Ychou, Y. Humblet, O. Bouché, L. Mineur, C. Barone, A. Adenis, J. Tabernero, T. Yoshino, H. Lenz, R. Goldberg, D. Sargent, F. Cihon, L. Cupit, A. Wagner, D. Laurent (2013)Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
The Lancet, 381
Tianhong Li, Y. Ling, I. Goldman, R. Perez-soler (2007)Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non–Small Cell Lung Cancer Cells
Clinical Cancer Research, 13
A. Jemal, Melissa Center, C. DeSantis, E. Ward (2010)Global Patterns of Cancer Incidence and Mortality Rates and Trends
Cancer Epidemiology, Biomarkers & Prevention, 19
S. Stintzing, D. Modest, Lisa Rossius, M. Lerch, L. Weikersthal, T. Decker, A. Kiani, U. Vehling‐Kaiser, S. Al-Batran, T. Heintges, C. Lerchenmüller, C. Kahl, G. Seipelt, F. Kullmann, M. Stauch, W. Scheithauer, S. Held, C. Gießen-Jung, M. Moehler, A. Jagenburg, T. Kirchner, A. Jung, V. Heinemann (2016)FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
The Lancet. Oncology, 17 10
(1909)Randomized trial of TAS102 for refractory metastatic colorectal cancer
W. John, J. Picus, C. Blanke, J. Clark, Lawrence Schulman, E. Rowinsky, D. Thornton, P. Loehrer (2000)Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma
M. Rothenberg, B. LaFleur, D. Levy, M. Washington, S. Morgan-Meadows, R. Ramanathan, J. Berlin, A. Benson, R. Coffey (2005)Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 36
V. Heinemann, L. Weikersthal, T. Decker, A. Kiani, U. Vehling‐Kaiser, S. Al-Batran, T. Heintges, C. Lerchenmüller, C. Kahl, G. Seipelt, F. Kullmann, M. Stauch, W. Scheithauer, Jörg Hielscher, M. Scholz, S. Müller, H. Link, N. Niederle, A. Rost, H. Höffkes, M. Moehler, R. Lindig, D. Modest, Lisa Rossius, T. Kirchner, A. Jung, S. Stintzing (2014)FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
The Lancet. Oncology, 15 10
E. Hawk, P. Limburg, J. Viner (2002)Epidemiology and prevention of colorectal cancer.
The Surgical clinics of North America, 82 5
I. Chau, D. Cunningham, T. Hickish, A. Massey, L. Higgins, R. Osborne, N. Botwood, A. Swaisland (2006)Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study.
Annals of oncology : official journal of the European Society for Medical Oncology, 18 4
J. Woodburn (1999)The epidermal growth factor receptor and its inhibition in cancer therapy.
Pharmacology & therapeutics, 82 2-3
N. Goldstein, M. Armin (2001)Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma
R. Mayer, E. Cutsem, A. Falcone, T. Yoshino, R. García-Carbonero, N. Mizunuma, K. Yamazaki, Y. Shimada, J. Tabernero, Y. Komatsu, A. Sobrero, E. Boucher, M. Peeters, B. Tran, H. Lenz, A. Zaniboni, H. Hochster, J. Cleary, H. Prenen, F. Benedetti, Hirokazu Mizuguchi, L. Makris, Masanobu Ito, A. Ohtsu (2015)Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
The New England journal of medicine, 372 20
Lin Wang, Zhi-xia Zhu, Wenying Zhang, Wei-Min Zhang (2011)Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in BXPC-3 and PANC-1 human pancreatic cancer cells.
Experimental and therapeutic medicine, 2 5
M. Moore, D. Goldstein, J. Hamm, A. Figer, J. Hecht, S. Gallinger, H. Au, P. Murawa, D. Walde, R. Wolff, D. Campos, R. Lim, K. Ding, G. Clark, T. Voskoglou-Nomikos, Mieke Ptasynski, W. Parulekar (2023)Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
Journal of Clinical Oncology, 41
J. Jassem, R. Ramlau, A. Santoro, W. Schuette, A. Chemaissani, Shengyan Hong, J. Blatter, S. Adachi, A. Hanauske, C. Manegold (2008)Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 10
M. Resnick, J. Routhier, T. Konkin, E. Sabo, V. Pricolo (2004)Epidermal Growth Factor Receptor, c-MET, β-Catenin, and p53 Expression as Prognostic Indicators in Stage II Colon Cancer
Clinical Cancer Research, 10
A. Wells (1999)EGF receptor.
The international journal of biochemistry & cell biology, 31 6
J. Moyer, E. Barbacci, K. Iwata, L. Arnold, B. Boman, A. Cunningham, Catherine DiOrio, Jonathan Doty, M. Morin, M. Moyer, M. Neveu, V. Pollack, L. Pustilnik, M. Reynolds, D. Sloan, A. Theleman, P. Miller (1997)Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.
Cancer research, 57 21
(2001)Stage IV colon adenocarcinoma : implications for a standardized scoring system
S. Lim, Sujin Lee, Jeeyun Lee, S. Park, Joon-Oh Park, Y. Park, Ho Lim, W. Kang, S. Kim (2018)Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial
Journal of Cancer, 9
Edward Kim, F. Khuri, R. Herbst (2001)Epidermal growth factor receptor biology (IMC-C225)
Current Opinion in Oncology, 13
R. Akita, M. Sliwkowski (2003)Preclinical studies with Erlotinib (Tarceva).
Seminars in oncology, 30 3 Suppl 7
BackgroundDespite new agents to treat metastatic colorectal cancer (CRC), patients eventually progress and additional therapies are needed.ObjectiveWe intended to evaluate the combination of pemetrexed/erlotinib in patients with high epidermal growth factor receptor (EGFR)-expressing (2+ or 3 on immunohistochemistry) metastatic CRC who experienced disease progression after standard chemotherapy.Patients and methodsWe investigated pemetrexed and erlotinib (pemetrexed 500 mg/m2 on Day 1 and erlotinib 100 mg/m2 on Days 1–21) as a salvage treatment, given every 3 weeks, until disease progression or intolerable toxicity. The primary outcome was overall response rate (RR).ResultsFrom May 2017 to April 2018, 29 metastatic CRC patients with high EGFR expression who had previously received standard therapies were enrolled into this trial. The regimen was well tolerated. Skin rash, vomiting, fatigue, and anorexia were common toxic effects but were mostly manageable and controllable side effects of grades 1 or 2 only. In an intent-to-treat analysis, three partial responses (PRs) were observed in enrolled patients, revealing an overall RR of 10.3%. This value supported the statistical hypothesis of this study. Fifteen patients had stable disease and the disease control rate (DCR) was 62.1%. All three patients who achieved a PR had a tumor EGFR expression of 3+. Among the eight patients with EGFR 3+ expression, the RR and DCR were 37.5% and 75.0%, respectively.ConclusionThis phase II trial using pemetrexed/erlotinib in metastatic CRC with high EGFR expression met the primary endpoint of tumor response.Trial RegistrationThis study was registered at ClinicalTrials.gov (number NCT03086538).
Targeted Oncology – Springer Journals
Published: Feb 9, 2020
Access the full text.
Sign up today, get DeepDyve free for 14 days.